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triple negative subtype in hispanic/latina women
Kristin Anderson1, Patricia A Thompson2, Betsy C Wertheim2, Lorena Martin3, Ian K Komenaka4, Melissa Bondy5,
Adrian Daneri-Navarro6, Maria Mercedes Meza-Montenegro7, Luis Enrique Gutierrez-Millan8, Abenaa Brewster9,
Lisa Madlensky1,3, Malaika Tobias1, Loki Natarajan1,3 and María Elena Martínez1,3*Abstract
Familial breast and ovarian cancer prevalence was assessed among 1150 women of Mexican descent enrolled in a
case-only, binational breast cancer study. Logistic regression was conducted to compare odds of triple negative
breast cancer (TNBC) to non-TNBC according to family history of breast and breast or ovarian cancer among 914 of
these women.
Prevalence of breast cancer family history in a first- and first- or second-degree relative was 13.1% and 24.1%,
respectively; that for breast or ovarian cancer in a first-degree relative was 14.9%. After adjustment for age and
country of residence, women with a first-degree relative with breast cancer were more likely to be diagnosed with
TNBC than non-TNBC (OR=1.98; 95% CI, 1.26–3.11). The odds of TNBC compared to non-TNBC were 1.93 (95% CI,
1.26–2.97) for women with a first-degree relative with breast or ovarian cancer. There were non-significant stronger
associations between family history and TNBC among women diagnosed at age <50 compared to ≥50 years for
breast cancer in a first-degree relative (P-interaction = 0.14) and a first- or second-degree relative (P-interaction = 0.07).
Findings suggest that familial breast cancers are associated with triple negative subtype, possibly related to BRCA
mutations in Hispanic/Latina women, which are strongly associated with TNBC. Family history is an important tool to
identify Hispanic/Latina women who may be at increased risk of TNBC, and could benefit from prevention and early
detection strategies.
Keywords: Triple negative breast cancer; Hispanic; Family history; Risk factor heterogeneityBackground
Having a first-degree relative with breast cancer is asso-
ciated with a 2-fold increase in risk of developing the
disease, despite the fact that mutations in high-risk al-
leles such as BRCA1/2 explain less than 20% of familial
cancers (Collaborative Group on Hormonal Factors in
Breast, C 2001, Mavaddat et al. 2010). Breast cancer is a
heterogeneous disease with differences in patient out-
comes based on tumor hormone receptor status and ex-
pression of human epidermal growth factor receptor 2
(HER2). Gene expression studies have confirmed the ex-
istence of at least four distinct and reproducible breast* Correspondence: e8martinez@ucsd.edu
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in any medium, provided the original work is pcancer subtypes with molecular differences based on these
markers (Perou et al. 2000). These differences have re-
sulted in stratification in the clinical setting with varying
treatment algorithms based on subtype (Paik et al. 2006,
Slamon et al. 2011).
Epidemiological studies provide additional evidence
supporting differential effects of reproductive risk factors
on risk of developing hormone receptor positive or nega-
tive tumors, as we recently reviewed (Anderson et al.
2014), which also include case-only studies (Martinez
et al. 2010). Non-reproductive risk factors, such as obesity,
have also been shown in a recent meta-analysis to confer a
greater risk for triple negative breast cancer (TNBC) com-
pared to non-TNBC, particularly among pre-menopausal
women (Pierobon and Frankenfeld 2013). Results of some
studies, which are reviewed here (Additional file 1: Table S1),
have also shown differences in risk by subtype according to
family history, but results are inconsistent. These findingsis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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mors. Furthermore, genetic variation in susceptibility to
breast cancer within certain racial/ethnic populations,
along with interactions of these heritable risk factors with
environmental and reproductive risk factors, may contrib-
ute to differences in breast cancer risk and outcomes by
tumor subtype.
Relatively little data exist on risk of breast cancer asso-
ciated with family history of breast and ovarian cancers
in Hispanic/Latina women, and fewer reports have been
published on associations by tumor subtype (Hines et al.
2008, Jiang et al. 2012). Furthermore, there is a paucity
of information on the family history profile of breast and
ovarian cancer in this ethnic group. Such information
could help identify the degree of misreporting due to
lack of awareness or limited family structure, resulting
from few female family members who have survived to
older ages (Weitzel et al. 2007a). Importance of im-
proved family history ascertainment relates to the recent
publication of Hispanic/Latina breast and ovarian cancer
families in the U.S. that showed a high prevalence of
BRCA mutations (25%) (Weitzel et al. 2013).
To address these important gaps, here we first de-
scribe the self-reported breast and ovarian family history
profile in a breast cancer case series of women of
Mexican descent. We then assess odds of TNBC accord-
ing to family history of breast and ovarian cancer.
Methods
Study population
The Ella Binational Breast Cancer Study is a case-only
study of invasive breast cancer; details of the study have
been previously described (Martínez et al. 2010). Mexican
and Mexican-American women age 18 years or older were
recruited within 24 months of diagnosis. Recruitment sites
included two in the U.S. (the University of Arizona Cancer
Center in Tucson, Arizona and the M.D. Anderson Can-
cer Center in Houston, Texas) and three in Mexico (the
Universidad de Sonora in Hermosillo, Sonora; the Insti-
tuto Tecnológico de Sonora in Ciudad Obregón, Sonora;
and the Universidad de Guadalajara in Guadalajara,
Jalisco). All sites used a predominately clinic-based re-
cruitment strategy. Recruitment occurred from March
2007 through June 2011, with response rates ranging from
95-99% (Martínez et al. 2010). The Institutional Review
Board from each participating institution approved the
study protocol, and all women provided informed consent.
IRB approvals: 1. UCSD Human Research Protections
Program; 2. University of Arizona Human Subjects Pro-
tection Program; 3. The University of Texas MD Anderson
Cancer Center Institutional Review Board; 4. Commis-
sion on Ethics, Investigation and Biosafety, University of
Guadalajara; 5. Committee on Ethics, Instituto Jaliscience
de Cancerologia; 6. National Commission on ScientificResearch of the Instituto Nacional del Seguro Social; 7.
Bioethics Institutional Committee, Instituto Tecnologico
de Sonora.
Data collection and variable definition
Risk factor data were ascertained from an interview-
administered questionnaire that included sociodemo-
graphics, reproductive history, family history of cancer,
and other risk factor data. Details were previously pub-
lished (Martínez et al. 2010, Martinez et al. 2013) and
are further described below.
Comprehensive family history data were collected to
include first-degree (brother, sister, son, daughter, father,
mother) and second-degree (grandfather, grandmother,
uncle, aunt) relatives. Half-siblings were not included. A
total of 1150 participants were asked, “Have any of your
immediate family members ever been diagnosed with
cancer?” Those who answered “yes” (n = 612) were then
asked to report the type of cancer for each family mem-
ber and his/her age at diagnosis. Women who answered
“no” (n = 510) or “don’t know” (n = 28) did not supply
any additional information regarding family history of
cancer. We also asked participants whether they were
adopted and, if so, whether they knew her blood rela-
tives. A woman who reported that she was adopted and
did not know her blood relatives was categorized as
“don’t know”; adopted women who knew their blood rel-
atives were categorized as positive or negative for family
history according to their response.
For breast or ovarian cancer family history, we counted
the number of women who reported a history of these ma-
lignancies in first- or second-degree relatives. Women
who reported a female relative with cancer of unknown
type were classified as “unknown” for the relevant family
history variables, depending on whether the relative in
question was first or second degree, which contributed to
differences in the denominators available for each variable.
Clinical data
Age at diagnosis and tumor marker data for estrogen re-
ceptor (ER), progesterone receptor (PR), and HER2 were
abstracted from medical records. In the abstraction, pri-
ority was given to a numeric value for the percent of
cells staining, where ER and PR positivity was defined
as ≥ 1% cell staining by immunohistochemistry (IHC).
Cases were considered HER2+ if amplified as deter-
mined by fluorescence in situ hybridization (FISH; ra-
tio ≥ 2.2). If no FISH results were available, an IHC
intensity score of 3/3+ was considered positive, 2/2+
equivocal, and 0/1/1+ negative. If the IHC intensity score
was 3/3+, that tumor was classified as HER2+ regardless
of FISH value. Tumors with an equivocal HER2 IHC in-
tensity score and no FISH data were excluded (n = 53).
Cases were categorized as either TNBC (ER–, PR–, and
Table 1 Summary of family history of breast and/or
ovarian cancer in the Ella study
Family history characteristic n/total (%)
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and/or PR+ and HER2–), luminal B (ER+ and/or PR+ and
HER2+), and HER2+ (ER-/PR- and HER2+) cancers. Of
the 1150 women who were asked about their family his-
tory, 960 had known TNBC status, of which 914 had
known status for family history of breast cancer in a first-
or second-degree relative.Unknown due to adoption
(participant does not know her blood relatives)
9/1150 (0.78)
Unknown (other reason) 19/1150 (1.65)
Family history of breast cancer
In a first-degree relative 146/1112 (13.1)
In a first- or second-degree relative 264/1096 (24.1)
In a first- or second-degree relative and
participant’s age of diagnosis < 50 y
138/504 (27.4)
Family history of breast or ovarian cancer
In a first-degree relative 166/1112 (14.9)
In a first- or second-degree relative 293/1096 (26.7)
In a first- or second-degree relative and
participant’s age of diagnosis < 50 y
147/504 (29.2)






Number of first- or second-degree relatives
with breast or ovarian cancerStatistical analysis
Descriptive statistics (mean ± SD and proportions) for
family history and risk factor characteristics were calcu-
lated. Associations between family history and TNBC
status were tested using logistic regression, using non-
TNBC as the reference group. Since the primary object-
ive was to quantify the associations between presence of
family history of breast cancer and TNBC as a means of
understanding tumor heterogeneity rather than building
risk models, the models were adjusted only for age at
diagnosis (continuous) and recruitment country (U.S. or
Mexico). In addition, we found minimal differences in
the distributions of reproductive factors by family his-
tory, suggesting a lack of confounding by these variables.
Analogous models were conducted for family history of
breast or ovarian cancer. Each model generated an odds
ratio (OR) and 95% confidence interval (CI). Tests for
interaction between age and family history on TNBC sta-
tus were conducted using likelihood ratio tests. All statis-
tical analyses were performed using Stata 13.1 (StataCorp,




*No participants reported more than 3 first-degree relatives with breast or
ovarian cancer.Results
A family history of breast cancer in a first-degree relative
was reported by 13.1% of participants, and 24.1% re-
ported breast cancer in a first- or second-degree relative
(Table 1). The prevalence of a reported history of breast
or ovarian cancer in a first-degree relative was 14.9%.
Among women who were diagnosed at age <50 years,
the prevalence of family history of breast cancer in a
first- or second-degree relative increased to 27.4%. Few
women reported more than one relative with breast or
ovarian cancer.
Table 2 shows age and reproductive factors of women
with at least one first-degree relative with breast cancer
compared with women with no affected first-degree rela-
tives. Analysis was restricted to the 914 women who had
data for tumor subtype and knowledge of their family
history of breast cancer in any relative. The mean age at
diagnosis was similar between the two groups, as was
parity, age at first full-term pregnancy, menstrual his-
tory, and breastfeeding history. However, differences by
country of residence were shown for family history,
wherein women recruited from Mexico were less likely
to report a family history than women from the U.S.Among women with non-TNBC, 13.5% had a family
history of breast cancer in a first-degree relative, com-
pared with 21.6% of women with TNBC (Table 3). The
prevalence of a family history of breast or ovarian cancer
in a first-degree relative was 15.5% among patients with
non-TNBC, compared with 24.3% among women with
TNBC. After adjustment for age and country of resi-
dence, the OR (95% CI) for TNBC versus non-TNBC for
women with a history of breast cancer in a first-degree
relative was 1.98 (1.26–3.11), and that for women with
an affected first- or second-degree relative was 2.04
(1.40–2.98). The odds of TNBC compared to non-TNBC
were 1.93 (95% CI, 1.25–2.97) for women with a first-
degree relative affected with breast or ovarian cancer.
We next conducted stratified analysis by age at diag-
nosis of the participant (Table 4). For all family history
variables assessed, we observed a trend towards stronger







n (%) n (%)
Age at diagnosis, y
< 50 58 (43.0) 361 (46.3)
≥ 50 77 (57.0) 418 (53.7)
Mean ± SD 53.6 ± 12.0 52.1 ± 12.4
Age at menarche, y
<13 65 (48.1) 346 (44.4)
≥ 13 70 (51.9) 433 (55.6)
Mean ± SD 12.6 ± 1.6 12.8 ± 1.7
Parity
Nulliparous 13 (9.6) 75 (9.6)
1–2 children 36 (26.7) 244 (31.3)
≥ 3 children 86 (63.7) 460 (59.1)
Mean ± SD 3.3 ± 2.2 3.1 ± 2.3
Age at first full term pregnancy, y
< 21 41 (33.6) 288 (40.9)
21–24 38 (31.1) 183 (26.0)
≥ 25 43 (35.2) 232 (33.0)
Unknown 0 1 (.1)
Nulliparous 13 75
Mean ± SD 23.4 ± 5.6 22.8 ± 5.4
Time since last full-term pregnancy, y
> 10 40 (69.0) 216 (60.7)
≤ 10 18 (31.0) 140 (39.3)
Postmenopausal or unknown 70 383
Premenopausal but nulliparous 7 40
Mean ± SD 12.8 ± 6.9 13.4 ± 8.0
Time from menarche to first
pregnancy, y
< 8 32 (26.2) 277 (39.3)
8–12 51 (41.8) 221 (31.5)
≥ 13 39 (32.0) 205 (29.1)
Unknown 0 1 (0.1)
Nulliparous 13 75
Mean ± SD 10.9 ± 5.6 9.9 ± 5.7
Lifetime duration of
breastfeeding, mo
Never 31 (25.4) 170 (24.1)
Up to 12 48 (39.3) 248 (35.2)
≥ 12 43 (35.2) 286 (40.6)
Nulliparous 13 75
Mean ± SD 15.6 ± 26.2 18.6 ± 31.5
Table 2 Risk factors in the Ella study by family history of
breast cancer* (n=914) (Continued)
Breastfeeding duration per birth, mo
Never 31 (25.4) 170 (24.2)
> 0–5 54 (44.3) 269 (38.2)
≥ 5 37 (30.3) 265 (37.6)
Nulliparous 13 75
Mean ± SD 4.5 ± 6.6 5.3 ± 6.8
Menopausal status at diagnosis
Pre 64 (47.8) 386 (50.2)
Post 70 (52.2) 383 (49.8)
Unknown 1 10
Age at menopause, y
< 50 41 (58.6) 226 (59)
≥ 50 29 (41.4) 157 (41)
Premenopausal at diagnosis 64 386
Unknown 1 10
Mean ± SD 46.9 ± 6.9 47.3 ± 6.5
Hormone replacement therapy
Never 117 (87.3) 674 (87.3)
Ever 17 (12.7) 98 (12.7)
Unknown 1 7
Hormone contraceptive use
Never 58 (43.0) 345 (44.3)
Ever 77 (57.0) 434 (55.7)
Tertile of duration of menstruation, y
7.6–27.35 21 (15.6) 172 (22.1)
27.4–33.45 40 (29.6) 201 (25.8)
33.5–50.5 65 (48.1) 343 (44)
Unknown 9 (6.7) 63 (8.1)
Mean ± SD 33.2 ± 6.7 32.1 ± 7.3
Country of residence
Mexico 46 (11.5) 355 (88.5)
U.S. 89 (17.3) 424 (82.7)
*History of breast cancer in one or more first-degree relatives.
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older (≥ 50 years) women.
Discussion
Our results support heterogeneity in risk of tumor sub-
type by family history, with TNBC having a stronger as-
sociation with a positive family history than non-TNBC
in this case series of women of Mexican descent. The
magnitude of the associations was similar among women
with breast cancer history in first-degree relatives, first-
or second-degree relatives, as well as those with history
of breast or ovarian cancer. There was a non-significant
Table 3 Odds of TNBC compared to non-TNBC according to family history of breast and/or ovarian cancer (n = 914)
Family history Non-TNBC TNBC TNBC vs. non-TNBC TNBC vs. non-TNBC
n (%) n (%) OR (95% CI)* OR (95% CI)**
Breast cancer in first-degree relatives
No 663 (86.6) 116 (78.4) 1.00 1.00
Yes 102 (13.5) 32 (21.6) 1.78 (1.14–2.77) 1.98 (1.26–3.11)
Breast cancer in first- or second-degree relatives
No 586 (76.5) 92 (62.2) 1.00 1.00
Yes 180 (23.5) 56 (37.8) 1.98 (1.37–2.87) 2.04 (1.40–2.98)
Breast or ovarian cancer in first-degree relatives
No 647 (84.5) 112 (75.7) 1.00 1.00
Yes 119 (15.5) 36 (24.3) 1.75 (1.13–2.67) 1.93 (1.25–2.97)
*Crude odds ratio.
**Adjusted for age at diagnosis and country of residence (U.S. or Mexico).
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positive family history among younger versus older women.
We conducted a review of the literature on prevalence
of family history of breast cancer by breast tumor sub-
type and found 28 studies that have evaluated this rela-
tionship: 17 case–control (Rosato et al, 2013; Kawai
et al, 2012; Bao et al, 2011; Yang et al, 2011; Dolle et al,
2009; Hines et al, 2008; Millikan et al, 2008; Yang et al,
2007; Rosenberg et al, 2006; Rusiecki et al, 2005; McCredie
et al, 2003; Cotterchio et al, 2003; Britton et al, 2002;
Huang et al, 2000; Yoo et al, 1997; Stanford et al, 1987;
McTiernan et al, 1986), 9 cohort (Su et al, 2011; Phipps
et al, 2011; Mavaddat et al, 2010; Setiawan et al, 2009;
Welsh et al, 2009; Margolin et al, 2006; Colditz et al,
2004; Tutera et al, 1996; Potter et al, 1995), and 2 case-Table 4 Odds of TNBC compared to non-TNBC according to fa
participant’s age at diagnosis
Family history Age of dia
TNBC
n/total (%)
Breast cancer in first-degree relatives
No 66/361 (18.3)
Yes 21/58 (36.2)
Breast cancer in first- or second-degree relatives
No 47/297 (15.8)
Yes 40/122 (32.8)
Breast or ovarian cancer in first-degree relatives
No 66/357 (18.5)
Yes 21/62 (33.9)
*Adjusted for country of residence (U.S. or Mexico).
**Interaction between age at diagnosis and family history on TNBC subtype.only studies (Song et al, 2013; Jiang et al, 2012) (Additional
file 1: Table S1). Prevalence of family history among
women with TNBC ranges from 5.3% in a Chinese case-
case study (Song et al. 2013) to 22% among women with
breast cancer age 40–84 years participating in the Breast
Cancer Surveillance Consortium (Phipps et al. 2011) and
22.6% among younger women (age < 45 years) with breast
cancer in the Seattle-Puget Sound area participating in a
case–control study (Dolle et al. 2009). Of the 28 studies,
only 9 assessed risk of TNBC compared to other subtypes
by presence of family history: 3 studies found evidence of
a stronger risk of TNBC compared to other subtypes
(Yang et al. 2007, Su et al. 2011, Yang et al. 2011); 3 studies
reported an elevated risk of TNBC as well as other sub-
types (Millikan et al. 2008, Dolle et al. 2009, Phipps et al.mily history of breast and/or ovarian cancer, stratified by
gnosis < 50 y Age of diagnosis ≥ 50 y
OR (95% CI)* TNBC OR (95% CI)*
n/total (%)
1.00 50/418 (12.0) 1.00
2.61 (1.43–4.77) 11/77 (14.3) 1.38 (0.68–2.83)
P-interaction = 0.14**
1.00 45/381 (11.8) 1.00
2.67 (1.63–4.37) 16/114 (14.0) 1.37 (0.73–2.56)
P-interaction = 0.07**
1.00 46/402 (11.4) 1.00
2.31 (1.28–4.18) 15/93 (16.1) 1.61 (0.85–3.06)
P-interaction = 0.36**
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TNBC (Welsh et al. 2009, Mavaddat et al. 2010); and one
case-case study was descriptive and reported no significant
differences for prevalence of family history by subtype
(Song et al. 2013). In our review, we could not find any
reports of family history and triple negative subtype in
Hispanic/Latina women, making ours the first to report
this association.
Compared to published reports on TNBC and family
history of breast cancer, more data exist from studies
that evaluated subtype based on only hormone receptor
status with no information on HER2. Among the 26
case–control or cohort studies included in this literature
review, 22 studies evaluated risk by hormone receptor
status. Of these, 2 studies found a stronger association
with ER+ versus ER– tumors (Welsh et al. 2009, Rosato
et al. 2013). Four studies reported a stronger association
for ER– versus ER+ tumors (Huang et al. 2000, Kawai
et al. 2012), with one study finding this relationship only
among Hispanic women (Hines et al. 2008) and another
showing that the association held only among women
with a first-degree relative diagnosed at age < 45 years
(Tutera et al. 1996). The remaining 16 studies found no
statistically significant differences in risk by hormone re-
ceptor status. Finally, the single published case-case
study is from a Spanish population, which showed ER–
or PR– cancers to be more likely than ER+ or PR+ to be
associated with family history, but only among women
age < 50 years (Jiang et al. 2012). It is important to note
that of the 28 studies included in this review, only 2 in-
cluded Hispanic/Latina women (Hines et al. 2008, Jiang
et al. 2012), which underscores the tremendous scarcity
of published data in this ethnic group.
Our findings are consistent with those of Hines et al.
(2008), who reported a higher risk of ER– tumors associ-
ated with family history of breast cancer among Hispanic
women in the southwestern U.S. Interestingly, they did
not observe this association among non-Hispanic whites,
a finding that further supports the potential role of BRCA
founder mutations in Hispanics (Weitzel et al. 2007b).
Weitzel et al. recently published results of a study of
Hispanic/Latina women living in the southwestern U.S.
who had either a personal or family history of breast and/
or ovarian cancer; deleterious BRCA mutations were de-
tected in 25% of participants (Weitzel et al. 2013). In a
second report of breast cancer cases in Mexico, such mu-
tations were detected in 28% of ovarian and 15% of breast
cancer cases (Villarreal-Garza et al. 2014). These results
suggest that BRCA mutations may account for a higher
percentage of familial breast cancer in women of Mexican
descent than in other racial/ethnic groups (Weitzel et al.
2013). Given that greater than 80% of BRCA mutated tu-
mors are known to be TNBC (Penault-Llorca and Viale
2012), this provides a viable explanation for our results.Recent studies of genetic variation and breast cancer risk
in Hispanic/Latina women have found further evidence of
unique genetic factors that are important in this popula-
tion (Fejerman et al. 2014). These findings further support
the need to incorporate both ancestry and family history
in studies of breast cancer risk factors.
It is recognized that accuracy in reporting family his-
tory of cancer is variable across studies, albeit reporting
of breast cancer history has been shown to be of higher
quality than that for other malignancies (Eerola et al.
2000, Murff et al. 2004, Mai et al. 2011). Family history
reporting has also been found to be more accurate
among first-degree relatives than second-degree or
more-distant relatives (Eerola et al. 2000, Ivanovich et al.
2002, Mai et al. 2011). Data are sparse on accuracy of
reporting of family history in different racial/ethnic or
immigrant populations. Orom et al. noted that reporting
is less accurate in immigrant groups and that non-white
immigrants are less likely to report a family history of
cancer than their white counterparts (Orom et al. 2008).
John et al. showed that foreign-born Hispanic women
reported a lower frequency of family history of breast
cancer than U.S.-born Hispanics, which was evident
among case and control women. Furthermore, there was
a clear and significant increasing trend in prevalence of
family history by level of acculturation in both pre- and
post-menopausal women (John et al. 2005). Our results
show that women in the U.S. had modestly higher self-
reported family history of breast cancer than those in
Mexico (17.3% versus 11.5%). This difference might re-
flect the underlying risk of breast cancer, awareness and
knowledge across sub-groups, or both.
In spite of the potential for misreporting of family his-
tory, reporting is unlikely to be influenced by tumor sub-
type, which gives credibility to our findings. In addition,
the fact that we observed consistently stronger, though
non-significant, associations between family history and
TNBC among younger women compared to older women
may also be indicative of the high prevalence of BRCA
mutation carriers in this population, who tend to be diag-
nosed with breast cancer at a younger age than do those
with sporadic cancers (Weitzel et al. 2013). These findings
underscore the importance of collecting a thorough family
history in the oncology clinic and primary care setting, as
it can affect approaches to prevention, treatment, and
overall risk assessment (Murff et al. 2004, Orom et al.
2008, Wideroff et al. 2010, Mai et al. 2011). A recent
American Society of Clinical Oncology consensus state-
ment provides guidelines on the collection and use of can-
cer family history data (Lu et al. 2014). According to the
guidelines, a minimum adequate family history for pa-
tients with cancer should include any family history in
first- or second-degree relatives, with the type and age at
diagnosis of each primary cancer. The history should be
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propriate referrals made to genetic counseling for high-
risk individuals.
Improvement in collection of family history through
new tools and instruments targeting English- and Spanish-
speaking Hispanic/Latina women in the U.S. should be a
priority for future research, especially given that this
group has been shown to be willing to participate in can-
cer genetic services (Ricker et al. 2006) and to embrace
and act upon genetic counseling and risk assessment in-
formation (Lagos et al. 2008). Identification of a strong
family history can ultimately affect treatment plans,
screening practices, and prevention options both for pa-
tients and their relatives, which may include genetic test-
ing for BRCA mutations.
Strengths of this study include the unique population
comprising a large case series of women of Mexican des-
cent residing in the U.S. and Mexico, as well as high par-
ticipation rates, ranging between 95–99% (Martínez et al.
2010). Though our sample size was large, it was not suffi-
ciently powered to allow for subset analyses based on age
of diagnosis for both the participant and their affected
first-degree relative. We had relatively few women report-
ing more than one affected relative and were thus unable
to conduct analyses based on number of affected relatives.
A further limitation of our study is that family history was
self-reported and unable to be verified, which may have
led to an underestimation of family history prevalence, as
noted above. Lastly, because our study employed a clinic-
based recruitment strategy and was not population-based,
findings may not be broadly generalizable to the Hispanic/
Latina community.Conclusions
In summary, results of the present study suggest a strong
familial cancer association with TNBC, supporting etio-
logic heterogeneity by tumor subtype in this population of
Hispanic/Latina women. This association may be related
to the prevalence of BRCA founder mutations in this
population, which are strongly associated with TNBC.
Family history is an important tool to identify Hispanic/
Latina women who may be at increased risk of TNBC,
and could benefit from prevention and early detection
strategies.Additional file
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